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Abstract
Background—Gynecology clinic-based studies have consistently demonstrated that induced
hypogonadism is accompanied by a decline in cognitive test performance. However, a recent study
in healthy asymptomatic controls observed that neither induced hypogonadism nor estradiol
replacement influenced cognitive performance. Thus the effects of induced hypogonadism on
cognition might not be uniformly experienced across individual women. Moreover, discrepancies
in the effects of hypogonadism on cognition also could suggest the existence of specific risk
phenotypes that predict a woman’s symptomatic experience during the menopause. In this study,
we examined the effects of induced hypogonadism and ovarian steroid replacement on cognitive
performance in healthy premenopausal women.
Methods—Ovarian suppression was induced with a GnRH agonist (Lupron) and then
physiologic levels of estradiol and progesterone were re-introduced in 23 women. Cognitive tests
were administered during each hormone condition. To evaluate possible practice effects arising
during repeated testing, an identical battery of tests was administered at the same time intervals in
11 untreated women.
Results—With the exception of an improved performance on mental rotation during estradiol,
we observed no significant effects of estradiol or progesterone on measures of attention,
concentration, or memory compared with hypogonadism.
Conclusions—In contrast to studies in which a decline in cognitive performance was observed
in women receiving ovarian suppression therapy for an underlying gynecologic condition, we
confirm a prior report demonstrating that short term changes in gonadal steroids have a limited
effect on cognition in young, healthy, women. Differences in the clinical characteristics of the
women receiving GnRH agonists could predict a risk for ovarian steroid-related changes in
cognitive performance during induced, and possibly, natural menopause. Key Words: estradiol,
hypogonadism, progesterone, cognition.
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The nature and magnitude of the effects of declining ovarian hormone secretion and the
onset of menopause on cognitive performance remain controversial. The plausibility of the
capacity of ovarian steroids to regulate cognitive performance in women is supported by two
types of evidence: 1) a multitude of studies in animals documenting the manifold
neuroregulatory actions of ovarian steroids (Diaz Brinton 2009; Dumitriu et al. 2010; Gibbs
2010; Kelly et al. 2009; Korol et al. 2002; McEwen 2010; Wise et al. 2005), and 2)
neuroimaging studies in humans demonstrating the modulatory effects of ovarian steroids on
brain activation patterns in regions implicated in the function of a wide range of cognitive
domains (Berman et al. 1997; Eberling et al. 2000; Goldstein et al. 2005; Maki et al. 2000;
Protopopescu et al. 2005; Rasgon et al. 2005; Resnick et al. 1998; van Wingen et al. 2007;
Yaffe et al. 1998). Nonetheless, several recent randomized clinical trials, including the
Women’s Health Initiative (WHI), have demonstrated that estrogen therapy has no direct
effect on cognitive performance in older postmenopausal women (Espeland et al. 2004;
Hogervorst et al. 2002; Lethaby et al. 2008; Low et al. 2006; Mulnard et al. 2000; Rapp et
al. 2003; Yaffe et al. 2006). In fact, the WHI findings suggest that estradiol increases the
risk of cognitive disorders (Shumaker et al. 2003; Shumaker et al. 2004). These findings
have been replicated in younger perimenopausal women (Maki et al. 2007), who frequently
report a decline in cognitive function during the perimenopause (Gold et al. 2000; Mitchell
et al. 2001) (although actual performance deficits have not been observed to accompany
these cognitive complaints in perimenopausal women (Fuh et al. 2006; Henderson et al.
2003; Kok et al. 2006)). In contrast to the randomized controlled trials of estrogen therapy,
observational studies more consistently report that estrogen therapy in young
perimenopausal women has long term beneficial effects on cognitive function and affords a
small reduction in the risk of dementia (Bagger et al. 2005; Henderson et al. 2005;
MacLennan et al. 2006; Whitmer et al. 2011; Yaffe et al. 1998; Zandi et al. 2002). The
remaining evidence suggesting a significant effect of estradiol on cognitive function to a
large degree is derived from clinic-based studies of hypogonadal women in whom surgical
oophorectomy was performed (Phillips et al. 1992; Sherwin 1988) or a GnRH agonist was
administered to suppress ovarian function as part of a treatment for an underlying
gynecologic condition (Craig et al. 2007; Craig et al. 2008; Grigorova et al. 2006; Palomba
et al. 2004; Sherwin et al. 1996; Varney et al. 1993). Although the specific cognitive
function that is reported to decline during hypogonadism varies across studies, a decline in
some aspect of cognitive performance is consistently observed during induced
hypogonadism (and in some studies, a subsequent improvement in performance after
estradiol therapy). Nonetheless, in contrast to the majority of clinic-based studies, a recent
study by Owens (2002) reported that four months of GnRH agonist-induced ovarian
suppression had no effect on cognitive performance measures in 16 asymptomatic healthy
premenopausal women. Thus, despite employing an identical hormonal manipulation (i.e.,
GnRH agonist-induced hypogonadism) and administering similar cognitive tests, the
findings in the Owens study (2002) are ostensibly at variance with numerous studies in
which a decline in at least one aspect of cognitive performance was observed.
Several potential confounds could account for discrepancies across studies including the
small effect sizes of the changes in cognitive outcomes measured, the presence of practice
effects after repeated testing, and differences in baseline cognitive performance in the
women prior to induced hypogonadism. Additionally, the clinical characteristics of the
samples also obviously differed between a selected sample of healthy women in the Owens
study compared with women receiving treatment for a gynecologic condition who
constituted the majority of the clinic-based studies. The difference between the cognitive
effects of induced hypogonadism in healthy women (observed by Owens (2002)) compared
with those in studies of gynecological clinic-based samples, therefore, could suggest a
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substrate of risk for a woman to experience a cognitive decline during an induced or natural
menopause. Moreover, confirmation of these differences could identify subgroups of women
who are differentially sensitive to changes in ovarian steroids and inform animal studies in
which the mechanisms underlying these differences could be explored.
As part of a larger study investigating the effects of ovarian steroids on brain function and
behavior, we had the opportunity to evaluate cognitive performance in a sample of
premenopausal women who were healthy and free of gynecologic disease. To further
examine the effects of ovarian steroids on measures of cognitive function in these women,
we administered a battery of cognitive tests under conditions of GnRH agonist-induced
ovarian suppression, and then repeated testing after replacement with physiologic levels of
estradiol (E) and progesterone (P), respectively. We, therefore, had the opportunity to ask
the following questions: First, do some cognitive tasks elicit hormone-related changes in
performance in healthy women. Second, do E and P mediate distinct changes in cognitive
test performance in these women?
METHODS
Subject Selection
a) Lupron-treated group (GnRH agonist-induced hypogonadism and hormone
replacement)—Subjects were 23 women (mean ± SD age = 35 ± 7 years) recruited
through advertisements in the hospital newsletter. All were medication free, and all were
screened for the absence of significant medical and gynecologic illness through history,
physical examination, and laboratory tests. All subjects were administered the Structured
Clinical Interview for DSM-III-R (Spitzer et al. 1990), to confirm the absence of current
Axis I psychiatric illness. The protocol was approved by the NIMH Intramural Research
Review Board, and written informed consents were obtained from all subjects. All women
completed an average of 16.2 ± 1.8 years of education.
b) Untreated Control group—To examine for possible practice effects arising during the
repeated testing that we performed in this protocol, we recruited a group of 11 healthy
women who served as an un-medicated [i.e., eugonadal] comparison group (mean ± SD age
= 33.8 ± 10.5). They received the same medical and psychiatric screening as the participants
who received Lupron, and all were medication free and had no medical, gynecologic, or
psychiatric illness, current or past. All women completed an average of 17.5 ± 1.6 years of
education.
Protocol (Figure 1)
a) Hormone manipulation group—Women received depot Lupron, (leuprolide acetate,
TAP Pharmaceuticals, Chicago, IL) 3.75 mg by intramuscular (IM) injection every four
weeks for five-six months. Lupron alone was administered for the first eight-twelve weeks.
Subjects then received, in addition to Lupron, 17 beta E (0.1 mg/day) by skin patch (Ciba
Geigy, Rariton, NJ) or P suppositories (200 mg b.i.d.) (NIH Pharmacy, Bethesda, MD) for
five weeks each. The two “addback” regimens were separated by a one week washout
period. Subjects were administered both patches and suppositories (active or placebo,
depending upon the treatment phase) daily throughout the entire addback period to ensure
the double-blind was maintained. The order of receiving E and P was randomly assigned and
counter-balanced. During the last week of E all subjects additionally received one week of P
suppositories to precipitate menses.
Cognitive testing was performed: at baseline prior to study (randomly across the menstrual
cycle), after six weeks of Lupron alone (hypogonadal), and after three to four weeks of
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hormone replacement (Lupron plus E and Lupron plus P). Mood symptoms were monitored
by the Beck Depression Inventory (BDI) (Beck et al. 1961), and the presence and severity of
hot flushes were measured by a daily self-rating scale (Endicott et al. 1981). All women
were paid for their participation according to NIH guidelines.
b) Untreated Control group—The women who served as controls for this study did not
receive Lupron at any time point and did not receive any hormone therapy, but received the
same battery of tests at similar time intervals as those in the main treatment protocol.
Blood samples were drawn at the time of testing in all women. The samples were
centrifuged, and aliquots of serum or plasma were frozen at −20°C until the time of assay.
Plasma levels of E and P (Abraham et al. 1971; Jiang et al. 1969) and total T (Furuyama et
al. 1970) were analyzed by radioimmunoassay.
Cognitive Tests – Table 4
Cognitive tests were selected to assess performance in the following cognitive domains:
verbal and visual memory, visuospatial ability, verbal fluency and articulation, motor speed
and dexterity, and attention and concentration. General ability was evaluated employing
components of the WAIS-R (Wechsler 1981), and the WRAT-R (Jastak et al. 1984). The
selection of cognitive tests was limited by the repeated measures design of this study, since
subjects were tested on four separate occasions. We, therefore, selected cognitive tests (e.g.,
paragraph memory) in which at least four separate forms were available.
Statistical Analysis
First, data from the Lupron-treated women (i.e., hormone manipulation protocol) were
analyzed by analysis of variance with repeated measures (ANOVA-R; Systat, SPSS,
Chicago, IL). In these women, test scores at each time point were compared by ANOVA-R,
with hormone condition (baseline vs. hypogonadal vs. E replacement vs. P replacement) as
the within-subjects variable. Complete data sets were present for all tests except for four
(i.e., Line Orientation, Digit span, Fragmented Pictures, and Mental Rotation) in which two
women treated with Lupron in each test had unusable data during one hormone condition. If
the ANOVAs were significant, we performed post-hoc comparisons of cognitive test
performance during hormone replacement compared with hypogonadal and baseline
conditions and, additionally, compared the cognitive performance during hypogonadism
with baseline.
The principle focus of this study was whether significant changes in cognitive test
performance could be observed during the pharmacologically-induced hormone conditions.
The repeated testing in this protocol could give rise to practice effects that mistakenly could
be attributed to an effect of a specific hormone condition. Additionally, the testing in this
protocol occurred in a partially fixed order with the first and second testing sessions
occurring during baseline and hypogonadism, respectively. Given the partially fixed order of
our study, in a second analysis, we performed ANOVAs on the cognitive data from both the
Lupron-treated women and the untreated controls, who were tested at the same approximate
time intervals as in women receiving Lupron and hormone replacement. These data were
analyzed with Group (Lupron-treated and untreated controls) as the between subjects factor
and time (i.e., hormone condition in Lupron-treated women and time in the untreated
women). The absence of a significant main or interaction between group and time/hormone
condition would be consistent with a practice effect in that test measure. ANOVAs were
performed on both the cognitive test scores at each test phase and the change in test scores
between sessions. By so doing we could effectively identify many of the ostensible hormone
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condition-related changes in cognitive function that were simply a product of repeated
testing (i.e., practice effects).
Several secondary analyses evaluated potential confounds in the data. First, the ANOVA-R
in the women was repeated with each of the following as a between-subjects variable: 1)
phase of menstrual cycle (i.e., follicular (n = 15) vs. luteal (n = 8) during baseline testing,
and 2) hormonal milieu during baseline testing (i.e., plasma levels of P ≥ 2 ng/ml and/or E ≥
70 pg/ml (n = 10) vs. plasma levels of P < 2 ng/ml and E < 70 pg/ml (n = 13)). These two
analyses examined the potential impact of baseline hormonal status on the observed
performance across the different hormone conditions. Second, eight women reported the
presence of premenstrual symptoms (PMS) prior to study entry. Thus, ANOVA-R analyses
were repeated in the asymptomatic women without PMS (n = 15) to ensure that the pattern
of cognitive performance across each hormonal state was not confounded by the inclusion of
women reporting PMS (either due to differences in symptomatology at baseline or
differences in response characteristics during hormone replacement). Further, due to
baseline differences in BDI scores between women with and without reported PMS, the
ANOVA-R analyses were repeated with baseline BDI scores as a covariate. Third, in the
Lupron-treated women we examined the effects of age as a covariate in the first set of
ANOVAs. Fourth, in the Lupron-treated women we examined the effect on test scores of the
order of receiving estradiol or progesterone first during the replacement phase of the study.
Finally, several studies (LeBlanc et al. 2001; Maki et al. 2008; Yaffe et al. 1998) but not all
(LeBlanc et al. 2007) suggest an interaction between E’s observed effects on verbal memory
and hot flush-induced sleep disturbance. Thus, we examined differences (ANOVA-R) in the
severity of self-ratings of hot flushes and disturbed sleep (on the days of cognitive testing)
between women whose performance on selected tests improved and those whose
performance declined, from baseline to hypogonadism as well as from hypogonadism to E
replacement.
Age, baseline BDI scores and years of education in the Lupron-treated women and the
untreated control group were compared with Student’s t-test.
RESULTS
Lupron-treated women did not differ in age or years of education from the untreated control
group (p=ns). Baseline BDI scores were non-significantly higher in the Lupron-treated
women compared with the untreated control group (Student’s t30=1.7, p=ns) due to the
presence of several women with PMS in the Lupron-treated group (see below).
Effects of Hormone Condition on Cognitive Test Performance (Table 3 and Supplemental
Table 1)
In the first analysis of only the data from the Lupron-treated women, ANOVA-Rs were
significant for several cognitive tests (Table 3); however, with only a few exceptions (listed
below) identical differences in test performances also were observed in the comparison
subjects who remained eugonadal throughout the study. Thus, the potential differences
across hormone conditions in the Lupron-treated women were in large part effects related to
the repeated administration of these tests on performance scores. Significant effects across
hormone conditions that were not also present in the comparison group were observed in the
following tests: 1) mental rotation test (adjusted); 2) Porteus maze (immediate seconds); 3)
verbal fluency (number of words); 4) Purdue peg board (dominant hand); and 5) digit span.
Post-hoc testing examining these significant differences showed that performance in the
adjusted mental rotation test was significantly better during E compared with
hypogonadism. Other comparisons on this measure were not significant after correction for
multiple comparisons (Figure 2). The remainder of the significant paired comparisons
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reflected significant differences between one of the hormone conditions and baseline.
Specifically, performance scores were significantly better during P compared with baseline
conditions in the Porteus maze, verbal fluency, and the Purdue peg board. Additionally,
performance scores in the Porteus maze were significantly better during E compared with
baseline. Finally, performance in the digit span was significantly better during
hypogonadism compared with baseline.
The analysis of change scores showed a similar pattern of effects with no significant
treatment group by test session interactions, with the exception of two test scores. First, in
the scores of both dominant and nondominant finger tapping, we identified a significant
interaction that reflected an improved performance in the untreated controls during their
second test compared with their first test that was not observed in women receiving Lupron.
Second, in the symbol digit written test, the women receiving no medication performed
better during test session 3 compared with the other times, whereas women receiving
Lupron did not show substantial differences across time points.
When the women reporting PMS were excluded from the analyses a similar pattern of
effects (both non-significant and significant) were observed with the 15 asymptomatic
women, although fewer test scores showed significant differences due to the reduced sample
size. Finally, in the Lupron-treated women, there were no significant main or interactive
effects with age on any test score, nor was there a significant effect of the order of receiving
estradiol or progesterone first during the replacement phase of the study.
Mood Symptoms and Hot Flushes
No significant changes in BDI scores were observed across hormonal conditions. However,
since we observed higher BDI scores at baseline prior to study entry in the eight women
reporting PMS compared to controls, baseline BDI scores were included as a covariate. The
pattern of results did not differ from that observed in the original analysis. Women
experienced a significant increase in the severity of hot flushes during the hypogonadal
state: all women reported hot flushes during hypogonadism, and none of the women
reported hot flushes at baseline. For those tests in which the literature suggests an effect of
estradiol that could interact with symptoms (e.g., paragraph memory, MRT), differences in
self-reports of the severity of hot flushes or disturbed sleep did not distinguish the women
whose performance worsened from those whose performance improved during
hypogonadism or hormone replacement.
DISCUSSION
In this study we did not replicate previous reports that GnRH agonist (Lupron)-induced
ovarian suppression was accompanied by a decline in measures of cognitive performance.
Nor did we observe an estradiol-related improvement in cognitive test performance
(Grigorova et al. 2006; Kampen et al. 1994; Resnick et al. 1997; Sherwin et al. 1996). In
particular, we observed no changes in measures of attention, concentration, or memory
function (either verbal or visual). The majority of differences in cognitive performance in
women also were observed in the untreated control subjects over time. These differences in
cognition, then, are unlikely due to the effects of gonadal steroids but rather are “practice
effects” due to the repeated administration of these tests. Indeed, significant differences
across hormone conditions that were not mirrored in the comparison group reflected either
improvements during E or P replacement compared with baseline (i.e., the first test session)
with no improvement compared with hypogonadism (when both E and P levels were
suppressed), or in the digit span test, a significant improvement during hypogonadism
compared with baseline that was maintained during estradiol and progesterone replacement.
One test, the digit span did show a difference between baseline and hypogonadism;
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however, the change in performance reflected an improvement not decline in performance
scores during hypogonadism. Moreover, the improved scores during hypogonadism were
virtually identical to those seen during gonadal steroid replacement, rendering a role for
changing gonadal steroid levels in the performance scores un-compelling. An analysis of
change scores across test sessions also failed to show specific effects of hormone condition,
and differences from the untreated control group were observed in only two tests both of
which reflected changes in the untreated controls not the women receiving Lupron. The only
test scores that improved during E compared with hypogonadism (i.e., age adjusted scores of
the mental rotation test) also were better (albeit not significantly so) during P compared with
hypogonadism and during E compared with baseline. The better performance on mental
rotation during E compared with baseline is not consistent with a specific effect of E on
performance since similar plasma E levels were observed during E and baseline. These data,
therefore, also suggest the absence of a specific effect of E levels on mental rotation
performance. Nonetheless, a previous study reported a significant improvement in mental
rotation performance scores in postmenopausal women after three weeks of estrogen therapy
(Duka et al. 2000). Our findings are consistent with the one prior study in healthy
asymptomatic young women, in whom cognitive testing was performed after four months of
GnRH agonist-induced ovarian suppression (Owens et al. 2002). While the effects of E (or
P) on cognitive function may vary with age (Rapp et al. 2002), our data and those of Owens
et al (2002) suggest that changes in the secretion of neither E nor P substantially alter
cognitive function in younger women, at least over the several weeks of exposure in this
protocol.
Previous studies examining the effects of E replacement in older hypogonadal (post-
menopausal) women identified positive effects on measures of verbal and visual memory in
some (Joffe et al. 2006; Kampen et al. 1994; Maki et al. 2001; Resnick et al. 1997) but not
all studies (Berman et al. 1997; Keenan et al. 2001; LeBlanc et al. 2001; Shaywitz et al.
1999). Additionally, several neuroimaging studies have identified changes in brain activity
corresponding to changes in ovarian steroid hormone secretion (Berman et al. 1997;
Goldstein et al. 2005; Protopopescu et al. 2005; Shaywitz et al. 1999; Smith et al. 2006; van
Wingen et al. 2007). We were unable to identify significant declines in performance scores
during hypogonadism, in tests of attention or verbal or visual memory, nor improvements
during E replacement in this study. Two meta analyses (LeBlanc et al. 2001; Yaffe et al.
1998) suggested that the beneficial effects of E on cognition are restricted to symptomatic
hypogonadal women. Nonetheless, the severity of hot flushes and disturbed sleep did not
distinguish those women in our study whose performance on the paragraph memory
improved from hypogonadism to E replacement and those whose performance declined. Our
finding that individual self-reports of neither hot flushes nor disturbed sleep impact
cognitive performance are consistent with two recent reports in symptomatic peri- and
postmenopausal women (LeBlanc et al. 2007; Maki et al. 2008); however, in one of these
studies (Maki et al. 2008), objective measures of hot flushes suggested that the number of
objective hot flushes (which exceeded the numbers recorded by self-report) was associated
with declines in verbal memory performance. Thus it is possible that had we employed
objective measures of the numbers of hot flushes experienced by each woman we might be
able to better distinguish those women who experienced an improvement in verbal memory
between the hypogonadal and estradiol replaced testing sessions. In our study, we also were
limited in the choice of testing measures due to the repeated measures design (e.g., four
separate test forms were not available for the CVLT) (Keenan et al. 2001). Alternate
measures may have been more sensitive to differences in hormone-induced changes in
memory function. However, several methodologic differences may explain the discrepancies
between our findings and those reporting E-related memory improvements. First, cross-
sectional studies in E users and non-users may reflect more enduring characteristics, such as
education and general health, rather than the use of E replacement (Yaffe et al. 1998).
Schmidt et al. Page 7










Second, our younger sample permits no conclusion about potential age-related decline in
verbal or working memory, which may be E-responsive (Rapp et al. 2002). Third, the
healthy paid volunteers in this study were recruited from a local catchment area surrounding
the hospital. Thus it is possible that our selection process could have introduced a bias that
resulted in a more motivated group of women whose performances would be different from
the scores of women studied in the clinic-based studies of treatment-seeking women.
Finally, the duration of hypogonadism in postmenopausal women would be considerably
longer than in our study and may be associated with a differing responsivity to E (Tinkler et
al. 2002).
Several previous reports examined the effects of GnRH agonist-induced hypogonadism, and
in some E replacement, on cognition in younger women receiving treatment for uterine
fibroids or endometriosis (Grigorova et al. 2006; Sherwin et al. 1996). In contrast to our
data, (Craig et al. 2007; Craig et al. 2008; Craig et al. 2008; Palomba et al. 2004; Varney et
al. 1993) the majority of these studies observed a significant decline in cognitive
performances during hypogonadism compared with baseline, including measures of verbal
memory, working memory, and visual recognition, and an improvement in several of these
measures (e.g., verbal memory) in those women receiving E (but not in those receiving
placebo) while on GnRH agonist. Our findings are consistent with those of Owens (2002),
who also studied asymptomatic healthy women at baseline and under conditions of GnRH
agonist-induced ovarian suppression of four months duration and, in half of the women,
after estradiol replacement. Both our study and that of Owens (2002) observed numerous
practice effects after repeated testing but no specific effects of either hypogonadism or
estradiol replacement despite administering similar test measures as those administered in
several gynecologic clinic-based studies. Together, our data and those of Owens (2002)
represent experience with over 30 healthy asymptomatic women (as well as 8 women
reporting PMS who were otherwise gynecologically normal) showing a consistent lack of
effect on cognitive performance after a decisive hormone intervention (i.e., ovarian
suppression). These findings in healthy asymptomatic women also stand in remarkable
contrast to the otherwise uniform findings in multiple studies of a decline in cognitive
performance in women treated with ovarian suppression for gynecologic illness.
These ostensibly discrepant findings could reflect important differences in the clinical
characteristics of the samples that are associated with or are predictive of a decline in
cognitive function during either the natural or induced menopause. Epidemiologic studies in
women during the perimenopause would suggest that complaints of cognitive decline are not
uniformly reported by women (Gold et al. 2000; Mitchell et al. 2001), and some women,
therefore, might be differentially vulnerable to the cognitive-impairing effects of declining
ovarian steroids. For example, the presence of endometriosis or fibroids could be associated
with a greater risk for cognitive decline under conditions of ovarian steroid withdrawal or
suppression. Abnormalities of estrogen receptor function have been suggested to play a role
in the pathophysiology of both of these conditions (Cavallini et al. 2011; Huhtinen et al.
2011; Li et al. 2001; Wei et al. 2007), and obviously both are treated in part by induced
hypogonadism. Thus it is possible that in women with endometriosis or uterine fibroids,
estrogen signaling is abnormal at other tissue sites including the brain, perhaps accounting
for the otherwise discrepant cognitive findings during GnRH agonist therapy. Alternately,
the symptoms of a longstanding gynecologic condition could be accompanied by increased
stress in these women. Chronic stress, in turn, could either diminish cognitive reserve or
impair ovarian estradiol secretion prior to treatment sufficient to amplify the effects of
GnRH agonist-induced hypogonadism on cognitive performance. Clearly other factors could
account for differences observed across studies including the baseline levels of cognitive
performance prior to starting GnRH agonist. Finally, mood symptoms may impair
performance and confound the effects of gonadal steroids on cognition. Mood symptoms,
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however, did not significantly differ between hypogonadal and hormone-replaced
conditions. We did observe mood symptoms in women who reported PMS at baseline.
Additional potential confounds related to the inclusion of women with PMS in this study
include the documented efficacy of GnRH agonist treatment in PMS and observations of
deficits in the retrieval of learned information that is menstrual cycle phase independent in
women with PMS (Keenan et al. 1992; Keenan et al. 1995). However, a similar pattern of
results was observed in the asymptomatic women without PMS who were analyzed
separately.
CONCLUSIONS
We did not find evidence that gonadal steroids regulate measures of cognitive function
including verbal memory or visuospatial abilities in younger healthy women. Our data in
women suggest that short term changes in either E or P do not substantially alter cognitive
test performance in any of the domains measured, including those previously reported to
change in the context of short term E therapy (Kampen et al. 1994) or across the menstrual
cycle (Hampson et al. 1988). However, the discrepancies between data collected from
gynecologic clinic-based samples and that from our study and that of Owens (2002) suggest
that, not surprisingly, the effects of E on the brain are not uniform across individuals. Such
differences further suggest the existence of as yet undefined risk phenotypes that might
predict an individual woman’s symptomatic experience during the menopause and her
possible response to estradiol therapy.
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All women received 3.75 mg of depot Lupron (leuprolide acetate, TAP Pharmaceuticals,
Chicago, IL) by intramuscular injection every four weeks for five-six months. The first
injection of Lupron was administered during the follicular phase between days 2–6 after the
onset of menses. Lupron alone was administered for the first eight-12 weeks. All women
then received, in addition to Lupron, 17 beta estradiol (0.1 mg/day) (E) by skin patch (Alora,
Watson Pharmaceuticals, Salt Lake City, UT) or progesterone suppositories (200 mg b.i.d.)
(P) (NIH Pharmacy, Bethesda, MD) for five weeks each. The two replacement regimens
were separated by a two week washout period. Subjects were administered both patches and
suppositories (active or placebo, depending upon the treatment phase) daily throughout the
entire replacement period to ensure the double-blind was maintained. During the last week
of E, all women received one week of active P suppositories in addition to E to precipitate
menses. All women received prepackaged one week unit-dose supplies of suppositories that
were formulated and coded (weeks 1–5) by the NIH Pharmacy Department.
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Performance scores (number of correct responses adjusted for age) on the Mental Rotation
Test during baseline (eugonadal), Lupron-induced hypogonadism, estradiol-, and
progesterone-replaced conditions (mean + SEM).
ANOVA-R demonstrated a significant effect of hormone condition in the group receiving
Lupron and hormone replacement that was not identified in the medication-free comparison
group. Post-hoc testing identified a significant improvement in the performance on the
Mental Rotation Test during estradiol replacement compared with hypogonadism (*p < .05).
However, there were no significant differences between baseline (eugonadal) and
hypogonadism or between progesterone and either hypogonadism or baseline conditions.
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Table 1
Baseline Demographics in Women treated with Lupron (n=23) and Untreated Controls (n=11)
Lupron-treated Group Untreated Control Group
Age# 35.0 (6.7) 33.8 (10.5)
No. of Years of Education# 16.2 (1.8) 17.5 (1.6)
Racial Distribution 21W/2AA 6W/1AA/4A
MC Phase during First Test Session 9Follicular/14Luteal 5Follicular/6Luteal
BDI Scores# 5.4 (9.4) 0.3 (0.5)
Values are Mean (SD) unless otherwise indicated.
Lupron-treated women did not differ in age, years of education, or baseline BDI scores from the untreated control group (p=ns for all comparisons).
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Table 2
Plasma Hormone Levels in Women treated with Lupron (n=23) and Untreated Controls (n=11)
Lupron-treated Gp. Baseline Hypogonadal E Replaced P Replaced
Estradiol (pg/ml) 84.3 (64.1) 18.9 (9.7) 108.9 (64.9) 16.4 (6.0)
Progesterone (ng/ml) 2.8 (4.3) 0.4 (0.2) 0.4 (0.3) 14.1 (7.6)
Untreated Control Gp Test # 1 Test # 2 Test # 3 Test # 4
Estradiol (pg/ml) 115.2 (72.1) 114.7 (77.6) 88.6 (57.7) 112.1 (75.8)
Progesterone (ng/ml) 2.2 (3.8) 3.9 (4.3) 4.8 (6.1) 4.0 (6.1)
Conversions - E: pg/ml × 3.67 = pmol/L; P: ng/ml × 3.18 = nmol/L.
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Table 4
Cognitve tests administered to Lupron-treated women and the untreated control group.
1) Rey complex figure (Corwin et al. 1993)
A figure is presented to the subject, who is asked initially to copy the figure. Scores reflect the amount of the figure (divided into
18 components) accurately copied, with each component rated on a scale from zero to two (Copy). The maximum score for the 18
components in the picture is 36. After a 1 to 1½ hour delay the subject is asked to draw the figure from memory, and the figure is
scored in a manner identical to that for the original copy (Delay).
2) Paragraph memory: logical memory test (Green et al. 1983; Talland 1965; Wechsler 1987)
A paragraph is read to the subject, who is asked to recall as much of the paragraph as possible (Immediate). After a 1 to 1½ hour
delay the subject is asked to recall the paragraph (Delay). Each paragraph ranges from 20 to 25 sections and the final score
represents a percentage of the paragraph recalled correctly. Two paragraphs were derived from each of the Wechsler adult
intelligence scale (Wechsler 1981) and the California Discourse Memory Test (Kramer et al. 1988; Lezak Deutsch 1995). The
administration of paragraphs was counterbalanced.
Spatial Ability
3) Line orientation (Benton et al. 1976; Benton et al. 1983)
A series of 15 cards is presented, and the subject is asked to match the angle of orientation of two lines on the card with those
numbered within a spectrum of lines on the reference card shown. Scores represent the number of correct paired (both line
pointing to the left and line pointing to the right matched correctly; maximum score = 15) (Pairs) and single matches (only one of
the paired lines being matched correctly; maximum score = 30) (Singles).
4) Mental rotation: figure rotation (Shepard et al. 1971; Vandenberg et al. 1978)
A series of geometrically complex objects are presented to the subject, who is asked to identify two matches from a group of four
similar objects (two of which are the original objects rotated in space). A 24-item test is administered. Scores include both the
number of correct matches (Total) as well as the number of matches that are adjusted for errors (Adjusted).
5) Embedded figures: hidden figures(Spreen et al. 1969)
Scores reflect the number of seconds to outline a given shape that is embedded in a more complex series of distracting lines
(average time for best three of four figures (Best) and for all four figures (All)).
6) Money road map (Money 1976)
A map in which the subject is required to report to the examiner the sequence of turns (left or right) involved in a specified route
going up to the top of the map and then coming down to the bottom of the map. Scores represent the number of seconds going up
(Time up), the number of seconds for the return trip (Time total), the number of errors going up (Errors up), and the number of
errors going down (Errors down).
7) Porteus maze (Porteus 1959)
Subjects are required to find the route to exit from the center of a maze. Scores consist of the number of seconds and the number
of errors (wrong directional decisions) made prior to exiting the maze (Immediate). After a 1 to 1½ hour delay the same maze is
presented to the subject, and both the seconds and the number of errors made in exiting are scored (Delay).
Verbal Fluency and Articulation
8) Verbal Fluency (Benton et al. 1976)
Subjects are asked to generate words beginning with a specific letter within a sixty second time period for each of three letters
(e.g., F, A, S). The score represents the combined number of words generated in three minutes for the three letters.
9) Stroop color naming (Stroop 1935)
Subjects are presented with a list of words consisting of the names of three colors (red, green, blue) in different order. The score
represents a T score reflecting the number of words correctly spoken in 45 seconds. (We did not employ this test as a measure of
perceptual interference.)
Motor Speed and Dexterity
10) Purdue pegboard (Spreen et al. 1991)
Scores represent the number of pegs inserted with the dominant hand alone (dominant), the non-dominant hand alone (non-
dominant), both hands (both), and an assembly task in which the pegs must be inserted in a particular order along with a washer
and a collar (assembly).
11) Grooved pegboard (Harley et al. 1980)
The subject is timed while inserting pegs in each of the grooved openings on the board. The scores consist of T scores reflecting
the time required for completion with the dominant (Dominant) and non-dominant (Non-dominant) hands.
12) Finger tapping (Kløve 1963; Reitan et al. 1993; Spreen et al. 1991)
Number of taps by dominant and non-dominant index finger in ten seconds are counted and averaged over three trials.
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Attention/Concentration
13) Digit span (Wechsler 1981)
Number of correct digits repeated (both forward and backward) after a list of digits has been read to the subject.
14) Symbol digit modalities (Smith 1982)
Subjects are presented with a group of digits that are paired with matching symbols. The subject is presented with a series of
symbols and must provide the corresponding digit of the pair from the sheet containing the correct match. Subjects are allowed 90
seconds to complete the task. The scores represent the number of correct written (Written) and oral (Oral) responses, as well as the
number of correct pair matchings from memory (Recall).
15) Trail making test (Benton et al. 1983; Kløve 1963; Reitan et al. 1993)
Scores represent the number of seconds required to connect points (numbers and letters) on a sheet of paper. Both the A and the B
forms were administered.
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